Halozyme wins Dutch court injunction blocking Merck Keytruda SC in eight European markets over EP622 patent

• Halozyme won a Dutch court injunction barring Merck’s Keytruda SC manufacture, sale, import, or stocking across several European markets.
• The Hague court found infringement of Halozyme’s EP 2,797,622 patent, rejecting Merck’s invalidity challenge.
• Order targets Merck’s European authorization holder MSD BV, restricting use of its marketing authorization to support affiliates.
• Keytruda’s IV version remains available, not covered by the injunction.
• Halozyme is also pursuing enforcement in Germany, where it won a preliminary injunction in December 2025, plus U.S. litigation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610070830PR_NEWS_USPR_____LA65803) on October 07, 2026, and is solely responsible for the information contained therein.